IMBCR is dedicated to advance the treatment of myeloma by connecting possibility through scientific innovation leading to personalized and continuous optimized patient care.
Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer
Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care
T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations
AI Tool May Predict Response, Resistance in Advanced RCC